Dr. Mark Stearns joins True Diagnostics Advisory Board

SAN DIEGO, CA -- True Diagnostics, Inc. announces that Dr. Mark Stearns has joined the Company’s Scientific Advisory Board.
Spread the Word
Listed Under

Medical Device
Prostate Cancer
Point Of Care


Carlsbad - California - US

Sept. 14, 2011 - PRLog -- SAN DIEGO, CA -- (09/15/11): True Diagnostics, Inc.™ (www.TrueDiagnostics.com) announces that Dr. Mark Stearns has joined the Company’s Scientific Advisory Board. Dr. Stearns is a tenured Professor in the Department of Pathology and Laboratory Medicine at Drexel University College of Medicine (DUCOM) in Philadelphia. He is the Director of Research and Head of the Prostate Cancer Research Program at DUCOM. His group has published over 100 peer reviewed papers on prostate cancer and developed a strong research program focused on drug discovery targeting metastatic prostate cancer. Dr. Stearns is also the founder and Chief Scientific Officer of Macroarray Technologies LLC, a biotech company involved in the development of diagnostic markers for prostate cancer. Dr. Stearns group’s long term focus is to develop a cure for metastatic prostate cancer.

Jerry Lee, President/CEO stated, “We are very pleased and fortunate to have Dr. Stearns join our Scientific Advisory Board. His passion for developing a cure for prostate cancer coincides directly with diagnostic tests for prostate health we have planned for our TrueDX™ Platform. We look forward to his involvement with our development activities as we continue to commercialize biomarkers onto our new TrueDX Platform.”

Dr. Stearns added, “The promise of proper medical treatment all starts with proper diagnosis. That’s exactly what they’re doing at True Diagnostics and I’m excited to be a part of helping to shape their direction.”

# # #

About the Company
True Diagnostics, Inc. creates diagnostic solutions for the $18 billion point-of-care IVD market. After 30 years in the global medical diagnostic field, the inventor of the pregnancy test created the TrueDX Platform which can measure the severity of any medical condition (using only a finger prick of blood, small urine or saliva sample, toxins, surface bacteria, and more), provide results in minutes (not days), and is portable. The TrueDX Platform takes point-of-care, point-of-incidence, and remote-of-care applications out of the lab to allow patient treatment to begin immediately. The flexibility of the TrueDX Platform creates unique and powerful opportunities for new diagnostic solutions through its ability to: 1) quickly bring new diagnostic tests to market; and, 2) open new geographic and application markets.

For more information, call 760-683-9158 or go to www.TrueDiagnostics.com

Jerry Lee, President/CEO
Source:Jerry Lee
Email:***@truediag.com Email Verified
Tags:Medical Device, Psa, Prostate Cancer, Diagnostics, Point Of Care
Location:Carlsbad - California - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse

Like PRLog?
Click to Share